Market Overview

Pete Najarian Sees Unusual Options Activity In SPDR S&P Biotech

Related XBI
Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates
Latest Tax Reform Bill From Senate GOP Seeks Repeal Of ACA Individual Mandate
The Psychological Requirements Of Successful Biotech Investing (Seeking Alpha)

On CNBC's "Fast Money Halftime Report", Pete Najarian spoke about high options volume in SPDR S&P Biotech (ETF) (NYSE: XBI).

He said that around 22,000 contracts of the November 90 calls were bought for $2. It's unusual to see that much volume in SPDR S&P Biotech, explained Najarian. The trade breaks even at $92 or 4.26 percent above the current market price. Najarian decided to follow the trade.

Posted-In: Fast Money Halftime Report Pete NajarianCNBC Options Markets Media ETFs


Related Articles (XBI)

View Comments and Join the Discussion!

Partner Center